ArticleDiscover oncology2026
A cancer neuroscience-related gene model for prognosis prediction and immunotherapy response evaluation in breast cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer prognosis remains challenging, and the emerging field of cancer neuroscience suggests that the nervous system plays a crucial yet underexplored role in tumor progression. This study aimed to construct and validate a novel prognostic signature for breast cancer based on genes involved in neural-tumor interactions.
methodsDifferential expression analysis and univariate Cox regression were performed on the TCGA-BRCA dataset to identify genes associated with both cancer neuroscience and patient prognosis. A prognostic model was constructed using LASSO and multivariate Cox regression analyses. Its predictive performance was validated in external datasets. The immune microenvironment, tumor mutation burden, and immunotherapy response were compared between the high- and low-risk groups. Drug sensitivity was predicted using the oncoPredict algorithm.
resultsA 12-gene prognostic model was developed. Patients stratified into high- and low-risk groups showed significant survival differences in all cohorts. The signature demonstrated reliable predictive accuracy, with AUCs of 0.700, 0.744, and 0.759 for 1-, 3-, and 5-year survival in the TCGA dataset. The low-risk group exhibited a more immunologically active tumor microenvironment,suggesting a potentially better response to immunotherapy. Drug sensitivity analysis identified three compounds with lower predicted IC50 values in the high-risk group.
conclusionThis study establishes and validates a novel 12-gene cancer neuroscience-related prognostic model for breast cancer. This model not only effectively stratifies patient risk but also reveals distinct immune landscapes and predicts differential responses to immunotherapy and potential therapeutic agents. These findings offer new insights for prognostication and personalized treatment strategies in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.